EDTA System for Reducing Browning in Mycohide Materials
20230146699 · 2023-05-11
Inventors
Cpc classification
C12N1/04
CHEMISTRY; METALLURGY
International classification
Abstract
A system and methods for reducing browning in fungal materials and objects therefrom, and in particular to a method for reducing browning in processed fungal materials. Provided are particular methods for reducing browning in fungal materials via application of a chelating agents, heat, a combination of chelating agents and heat, and various other processes described herein. Reduction of browning is applied to mycelium sheets in various wet processing stages including fermentation, plasticization, and in temperature treated samples. Reduced browning allows for control of the appearance of fungal biopolymers while also impacting mechanical properties such as tensile strength, tear strength, and abrasion resistance.
Claims
1. A system for reducing browning in fungal materials utilizing chelating agents and heat applied to mycelium sheets in various wet processing stages.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to enhance clarity and improve understanding of the various elements and embodiments of the invention, elements in the figures have not necessarily been drawn to scale. Furthermore, elements that are known to be common and well understood to those in the industry are not depicted in order to provide a clear view of the various embodiments of the invention. Thus, the drawings are generalized in form in the interest of clarity and concision.
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
DETAILED DESCRIPTION OF THE INVENTION
[0057] In the following discussion that addresses a number of embodiments and applications of the present invention, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. It is to be understood that other embodiments may be utilized and changes may be made without departing from the scope of the present invention.
[0058] Various inventive features are described below that can each be used independently of one another or in combination with other features. However, any single inventive feature may not address any of the problems discussed above or only address one of the problems discussed above. Further, one or more of the problems discussed above may not be fully addressed by any of the features described below. As used herein, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. “And” as used herein is interchangeably used with “or” unless expressly stated otherwise. As used herein, the term “about” means +/−5% of the recited parameter. All embodiments of any aspect of the invention can be used in combination, unless the context clearly dictates otherwise.
[0059] Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”. Words using the singular or plural number also include the plural and singular number, respectively. Additionally, the words “herein,” “wherein”, “whereas”, “above,” and “below” and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of the application. The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While the specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize.
[0060] As noted above, chelating agents like EDTA have been used previously in foods, pharmaceuticals, biomaterials and other industrial applications. Here, EDTA is employed in a unique manner in that it is being used for mycelial based biomaterial/bioleather browning reduction to facilitate the production of leather substitutes. Applications of the reduced browning methods described herein also include building material applications. In addition to the application of chelating compounds, other methods of browning reduction contemplated by the present inventors include: 1) heat (high temp >50 deg C, thereby inducing inhibition of all enzymes including PPOs that cause browning in mycelia), 2) high pH extractions (proteins including PPO enzymes are extracted out with alkaline solutions), 3) low pH treatment (low pH precipitates some of the PPO enzymes), and 4) application of antioxidant agents (reducing the antioxidant activity of PPOs).
[0061] In a preferred embodiment, the invention involves chelating agents like EDTA (“Ethylenediaminetetraacetic acid”) and others as possible agents used to reduce browning in mycelial biomaterials for various applications including fine mycelium. Chelating agents also render the mycelial material a lighter shade and/or form a white background, which improves aesthetics while enabling dyeing of the mycelial material with any light shade of color. Notably, EDTA treatment may be beneficially applied at any mycelium processing stem wherein the mycelium is saturated or moistened. The reduced browning methods described herein may be applied to any of the steps in the mycelium processing pipeline wherein the mycelia are in a wet or moist state, including during growth, post-harvest during plasticization, or during downstream and/or tanning steps.
[0062] As described above, the present invention further relates to a composition containing a dipping or soaking solution useful for at least one mycohide crust or sheet to be dipped or soaked therein, wherein the dipping or soaking solution contains at least one metalloproteinase inhibitor. In other embodiments, the metalloproteinase inhibitor is accompanied or followed by treatment in a solution of 15% ALE fatliquor+EDTA (either 1 mM or 5 mM EDTA). The metalloproteinase inhibitor can be a chelator, such as a chelator of a divalent metal ion (i.e., preferably EDTA or EGTA). As a non-limiting alternate example, the metalloproteinase inhibitor may be an aminocarboxylic acid or a polyaminocarboxylic acid or a salt thereof.
[0063] As a non-limiting example of a preferred embodiment, the metalloproteinase inhibitor may be ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as, for example, ethylenediaminetetraacetic acid disodium salt (Na2EDTA or disodium EDTA), ethylenediaminetetraacetic acid trisodium salt (Na3EDTA or trisodium EDTA), ethylenediaminetetraacetic acid tetrasodium salt (Na4EDTA or tetrasodium EDTA), ethylenediaminetetraacetic acid dipotassium salt (K2EDTA), ethylenediaminetetraacetic acid tripotassium salt (K3EDTA), ethylenediaminetetraacetic acid ammonium salt (NH4EDTA), or ethylenediaminetetraacetic acid diammonium salt ((NH4)2EDTA). As a non-limiting example, the metalloproteinase inhibitors may be ethylene glycol-bis((3-aminoethylether)-N,N,N′N′-tetraacetic acid (EGTA) or a salt thereof, such as, for example, the tetrasodium salt, Na4EGTA. Other non-limiting examples of metalloproteinase inhibitors include S,S′-ethylenediamine disuccinic acid (EDDS), 1,2-diaminocyclohexene-N,N,N′,N′-tetraacetic acid (CDTA) and N-(2-hydroxyethyl)ethylenediamine-N,N′-triacetic acid (HEEDTA).
[0064] Still other non-limiting examples of metalloproteinase inhibitors include methylglycinediacetic acid (MGDA), N,N-bis(carboxymethyl)glutamate (GLUDA), ortho-phenanthroline, 8-hydroxyquinoline, and phosphonic acid derivatives such as amino-tris methylene phosphonic acid, e.g., sold by Buckman Laboratories under the tradename “Phos 2”, diethylene triamine pentamethylene phosphonic acid, e.g., sold by Buckman Laboratories under the tradename “Busperse 254”, 2-phosphono-1,2,4-butanetricarboxylic acid, e.g., sold by Buckman Laboratories under the tradename “Phos 9”, hydroxyethylidene-diphosphonic acid, e.g., sold by Buckman Laboratories under the tradename “Phos 6”, or a blend of 2-methylpentanediamine tetrakis (methylene phosphonic acid) and 1,2, diaminocyclohexanetetrakis (methylene phosphonic acid), e.g., sold by Buckman Laboratories under the tradename “BPS 319.” Still other examples of metalloproteinase inhibitors include citric acid and salts of citric acid, gluconic acid, and salts of gluconic acid, cysteine, iodoacetic acid and sodium iodoacetate. Mixtures of any of the compounds named herein may also be used.
[0065] In some embodiments, the amount of the metalloproteinase inhibitor contained in the dipping or soaking solution is not critical and may be any amount effective to reduce browning in the treated mycohide sheets. As an example, the amount of the metalloproteinase inhibitor in the dipping or soaking solution can be from about 0.00001% to about 18%, from about 0.0001% to about 5%, or alternatively from about 0.001% to about 2% by weight based on the weight of the mycohide sheet contained in the composition. Alternatively, the amount of the metalloproteinase inhibitor in the dipping or soaking solution can be from about 0.00001% to about 10%, preferably from about 0.0001% to about 5% and most preferably from about 0.001% to about 2% by weight based on the dipping or soaking solution. The dipping or soaking solution can be any solution, such as, for example, an aqueous solution, that is used to treat mycohide sheets, including, but not limited to cleaning, chilling, curing, and/or solutions for softening or hydrating a mycohide sheet before or after plasticization and tanning.
[0066] In some embodiments, EDTA solution above 0.5 mM or above is used to treat mycelial material. Other chelating agents like EGTA (β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid), DTPA (diethylenetriaminepentaacetic acid) and GLDA (Dissolvine® GL is glutamic acid diacetic acid, tetra sodium salt) can be used to reduce browning in mycelial biomaterials as well. In a preferred embodiment, EDTA can be used in any form, including the non-salted form (i.e., Sigma Aldrich Product Number: E9884, Index-No.: 607-429-00-8, CAS-No.: 60-00-4). Preparation conditions for chelating agents vary. For example, the above-referenced EDTA (Product Number E9844) is prepared by dissolving in NaOH solution (i.e., 12 mM NaOH).
[0067] In some embodiments, the mycelium is heated at 50-70 deg C and EDTA treated. In another embodiment, under alternate conditions, heating is not implemented as EDTA alone provides a better equivalent impact. Notably, heating at scale is also a challenge, thus motivating the EDTA-only approach. As described below, optimal conditions were arrived at by first optimizing concentrations of EDTA and another chelating agent EGTA. A concentration of 5 mM EDTA was revealed to be the optimum concentration to achieve browning reduction. In some embodiments, non-salted EDTA concentrations can range from 2 mM to 12 mM (i.e., its solubility limit in alkaline solution). In a preferred embodiment, 5 mM is the ideal concentration to use for browning reduction, however lower EDTA concentrations will have an impact. For example, salted EDTA is used at concentrations exceeding 5 mM, including for example 6 mM, 8 mM, 10 mM, and 15 mM. Notably, chelating agents can be used in combination with heat or any other treatment that can reduce browning further.
[0068] In a preferred embodiment, the above-described treatments are implemented after harvest (last step of harvest/tending), plasticization, and all wet tanning operations as shown in
[0069] As shown in
[0070] Further to the above, physical and chemical methods are described that inhibit the activity of PPOs and thereby reduce browning in mycohide materials, including those previously subjected to plasticization processes. Relatedly,
[0071] In some embodiments, browning is a prevalent issue in mycohide cotton sheets in addition to felt sheets and plasticized sheets.
[0072] In a preferred embodiment, chelating agents like EDTA and EGTA are used to reduce browning in mycelial biomaterials for various applications including fine mycelium. In some embodiments, EDTA treatment may be beneficially applied at varying concentrations and at any mycelium processing step wherein the mycelium is saturated or moistened. For example,
[0073] The results from
[0074] In a preferred embodiment, a temperature condition of 50 deg C corresponds with a heat treatment period of 1, 2, or 3 hours. Relatedly, under standard conditions, a temperature condition of 60 deg C corresponds with a heat treatment time period of 1, 2, or 3 hours. In addition, under standard conditions a temperature condition of 70 deg C corresponds with a heat treatment time period of 0.5 hours, 1 hour, or 2 hours maximally. In some embodiments, a temperature condition of 80 deg C corresponds with a heat treatment time period of 0.5 hours, 1 hour, or 2 hours maximally. In other embodiments, a temperature condition of 90 deg C corresponds with a heat treatment time period of 0.5 hours, 1 hour, or 2 hours maximally. Notably, in some embodiments, other chelating agents like diethylenetriaminepentaacetic acid (“DTPA”), GLDA (i.e., Dissolvine GL; glutamic acid tetra sodium salt), and other chelating agents described above may be utilized for chelation activity. In other embodiments, the experiments detailed in
[0075]
[0076] In some embodiments, crusts are treated after fatliquoring (wet state) as shown in
[0077] In some embodiments, crusts are treated after fatliquoring in a dry state as shown in
[0078] As described above, browning is a prevalent issue in mycohide cotton sheets in addition to felt sheets and plasticized sheets.
[0079] In some embodiments, discoloration levels optimized to be EDTA treated are achieved at 30 C, 35 C, 40 C, and 45 C. Implementation of chelating agents and heat treatment strategies discussed above were also applied to both small scale and full size sheets (i.e., contemplated up to 10 ft, by 10 ft). In some embodiments, EDTA solution 14 is added during the tending step in fermentation, plasticization, and/or tanning step. Regarding heat treatment, heat treatment of sheet at the wet stage before plasticization is recommended.
[0080] Notably, browning/discoloration of mycohide is irreversible in some embodiments. Ideally, when handling harvested wet or plasticized sheets, browning reducing strategies are employed at the beginning of the plasticization process.
[0081] In general, mycelium sheets treated with EDTA have shown the best color uniformity. In contrast, heat treatment with or without EDTA does not show a consistent significant added effect. In some embodiments, it is not necessary to add additional EDTA during tanning (“D&S”) to sheets previously treated with EDTA during harvest or during plasticization. However, in a preferred embodiment, adding EDTA during tanning provided an added whitening effect, as shown in
[0082] In some embodiments, full sized cotton sheets are treated as defined by four groups: 1) plasticization without any treatment, 2) EDTA treatment only after harvesting sheets (5 mM EDTA 14 in water added on top of mycelia layer after harvest and gently massaged; then plasticize this section in glycerin/water solution), 3) EDTA treatment only during plasticization (plasticize in glycerin/water solution 40%/60% glycerin to water with EDTA at 5 mM), and/or 4) EDTA treatment on both harvested sheets and during plasticization (see above for conditions). Notably, in some embodiments, 5 mM EDTA and 16 mM NaOH are added for any step with EDTA treatment.
Fungal Materials and Methods
[0083] The base inoculum and growth conditions used to produce the reduced browning fungal material (the pre-reduced browning mycelium material) may be varied. The base mycohide is comprised of a fungal inoculum, the fungal inoculum prepared from a desired fungi strain. In some embodiments, the desired fungal strain can include any vegetative, sexual, or asexual structure of a fungus that is capable of growing a new fungal colony. Notably, regardless of the starting materials, subsequent plasticization allows for control of many useful fungal properties, including mechanical properties such as tensile strength, tear strength, abrasion resistance and other chemical properties such as dye fixation.
[0084] As described above, the present invention provides a system and methods for reducing browning in a fungal material that was comprised predominately of browned fungal tissues. As described above, referring to
[0085] As depicted in
[0086] As described above, the present invention provides a system and methods for reducing browning in a fungal material that was originally comprised predominately of fungal tissues. The origins of this initial fungal material comprising the pre-reduced browning mycelium material may be varied. In the preferred embodiment, this material is propagated from a colonizable substrate that has been inoculated with a chosen fungus. Preferred species include the Ganodermas, the order Polyporales generally, and including all saprobic fungal candidates that derive sustenance from lignin and cellulose-rich sources.
[0087] Below is provided an example of pre-reduced browning mycelium growth conditions. First, a fungal inoculum may be introduced into a substrate within an enclosure or prior to being introduced to the enclosure so as to provide an even distribution of fungus throughout. Next, the substrate is left to colonize. An intermediate layer is established on an open surface of the colonized substrate to control the interaction of the forming fungal tissue structure with the substrate. The presence of a uniform intermediate material atop the substrate enables a consistent surface from which the fungal tissues may grow, supporting uniform expansion of the fungal hyphae into the environment, and providing a determined space for manipulation by chemical and physical controls. Live fungal hyphae grow from the substrate and through the intermediate layer. In some instances, the living tissues that extend through the intermediate layer are manipulated to achieve a material having a desired thickness, shape, size and qualities.
[0088] Next, the intermediate layer may be delaminated from the nutrient source out of which it has grown to terminate further growth of the material, or the fungal tissue layer may be delaminated from the intermediate layer, which is left in place and optionally reused. The resultant living fungal tissue structures may optionally be fused with other living fungal tissue structures to create two-dimensional and three-dimensional structures. The final fungal tissue may then be subjected to post-growth processing to achieve desired properties for downstream usage.
[0089] The fungal substrate precursor material (“pre-reduced browning mycohide”) may be cultivated in either batch or continuous processes and the fungal tissues may be modified and directed during growth in order to achieve uniform characteristics across a surface, or be engineered to take on distinct local qualities through manipulation of growing tissue, or the addition of particles, fibers, meshes, fabrics, and other additives, armatures, and components. Fungal tissue sheets may be processed via cutting or other forming methods to obtain two-dimensional features and reliefs, or individual sheets may be stacked and grown together to form three-dimensional features, or composed with reinforcements or other structural amendments that may be incorporated into a growing tissue.
[0090] In some embodiments, reduced browning fungal materials described herein can behave and perform akin to an animal leather, common industrialized animal skin, or the like. This may be achieved based on the unique molecular structure of reduced browning chitin-based fungal materials and their composites. In some embodiments, post-processing of reduced browning fungal materials may be used to modify its structure or chemical composition, thereby conferring physical qualities according to desired applications.
[0091] The foregoing description of the preferred embodiment of the present invention has been presented for the purpose of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of the above teachings. It is intended that the scope of the present invention is not limited by this detailed description, but by the claims and the equivalents to the claims appended hereto.